RASEF

Summary

RASEF (RAS and EF-hand domain containing, HGNC:26464) is a protein-coding gene on chromosome 9q21.32, encoding Ras and EF-hand domain-containing protein (Q8IZ41). Rab GTPase that acts as a dynein adapter protein, thereby activating dynein-mediated transport and dynein-dynactin motility on microtubules.

This gene is a member of the Rab family of GTPases that are involved in regulation of membrane traffic. The encoded protein contains an N-terminal EF-hand domain, a coiled-coil motif and a C-terminal Rab domain. A potential role as tumor suppressor has been indicated for this gene.

Source: NCBI Gene 158158 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 151 total
• MANE Select transcript: NM_152573

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26464
Approved symbol	RASEF
Name	RAS and EF-hand domain containing
Location	9q21.32
Locus type	gene with protein product
Status	Approved
Aliases	FLJ31614, TSG
Ensembl gene	ENSG00000165105
Ensembl biotype	protein_coding
OMIM	611344
Entrez	158158

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000340717, ENST00000376447, ENST00000873431, ENST00000873432, ENST00000873433, ENST00000873434, ENST00000928035

RefSeq mRNA: 1 — MANE Select: NM_152573 NM_152573

CCDS: CCDS6662

Canonical transcript exons

ENST00000376447 — 17 exons

Exon	Start	End
ENSE00001090422	83012434	83012511
ENSE00001090425	83015805	83015900
ENSE00001090428	83022336	83022426
ENSE00001090432	83009641	83009756
ENSE00001293362	83007437	83007505
ENSE00001294194	83000896	83001130
ENSE00001295835	82979590	82982782
ENSE00001298797	83000169	83000316
ENSE00001299807	82992906	82993025
ENSE00001307793	83025775	83025921
ENSE00001308048	83005416	83005500
ENSE00001313770	83000433	83000570
ENSE00001317027	82990391	82990467
ENSE00001321082	82997012	82997126
ENSE00001328763	83004498	83004586
ENSE00001383554	82998365	82998446
ENSE00001391250	83062437	83063142

Expression profiles

Bgee: expression breadth ubiquitous, 182 present calls, max score 98.03.

FANTOM5 (CAGE): breadth broad, TPM avg 2.0821 / max 100.1381, expressed in 427 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
101128	1.2907	329
101127	0.3472	161
101125	0.1930	123
205534	0.1578	85
101126	0.0936	50

Top tissues by expression

242 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
epithelial cell of pancreas	CL:0000083	98.03	gold quality
ileal mucosa	UBERON:0000331	94.63	gold quality
sperm	CL:0000019	93.48	gold quality
mucosa of sigmoid colon	UBERON:0004993	92.72	gold quality
colonic mucosa	UBERON:0000317	91.65	gold quality
oviduct epithelium	UBERON:0004804	90.48	gold quality
pancreatic ductal cell	CL:0002079	90.42	gold quality
caput epididymis	UBERON:0004358	90.07	gold quality
esophagus squamous epithelium	UBERON:0006920	89.16	gold quality
epithelium of nasopharynx	UBERON:0001951	88.90	gold quality
secondary oocyte	CL:0000655	88.82	gold quality
bronchial epithelial cell	CL:0002328	88.74	gold quality
bronchus	UBERON:0002185	88.59	gold quality
body of pancreas	UBERON:0001150	88.45	gold quality
nasal cavity epithelium	UBERON:0005384	87.94	gold quality
trachea	UBERON:0003126	87.39	gold quality
palpebral conjunctiva	UBERON:0001812	87.36	gold quality
amniotic fluid	UBERON:0000173	87.17	gold quality
corpus epididymis	UBERON:0004359	86.64	gold quality
pancreas	UBERON:0001264	86.54	gold quality
nasal cavity mucosa	UBERON:0001826	85.23	gold quality
rectum	UBERON:0001052	85.00	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.10	gold quality
parotid gland	UBERON:0001831	83.92	gold quality
oocyte	CL:0000023	83.86	gold quality
pharyngeal mucosa	UBERON:0000355	83.59	gold quality
pylorus	UBERON:0001166	83.57	gold quality
islet of Langerhans	UBERON:0000006	83.36	gold quality
epithelium of mammary gland	UBERON:0003244	83.26	gold quality
mammary duct	UBERON:0001765	83.12	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-10018	yes	1105.93
E-ANND-3	yes	13.09
E-MTAB-7249	yes	11.13
E-MTAB-4850	no	5.38

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

155 targeting RASEF, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-548N	99.98	71.94	4170
HSA-LET-7F-2-3P	99.98	70.98	2588
HSA-MIR-1185-1-3P	99.98	71.04	2593
HSA-MIR-1185-2-3P	99.98	71.04	2593
HSA-MIR-4789-5P	99.98	70.76	2721

Literature-anchored findings (GeneRIF, showing 3)

• Homozygosity, in combination with methylation, appears to be the mechanism targeting RASEF in uveal melanoma, and allelic imbalance at this locus supports a TSG role for RASEF. (PMID:18385040)
• overexpression of RAB45 increased the phosphorylation levels of p38, resulting in the induction of apoptosis and inhibition of proliferation of CML progenitor cells (PMID:21890458)
• Near-genomewide RNAi screening for regulators of BRAF(V600E) -induced senescence identifies RASEF, a gene epigenetically silenced in melanoma. (PMID:24703243)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	rasef	ENSDARG00000076250
mus_musculus	Rasef	ENSMUSG00000043003
rattus_norvegicus	Rasef	ENSRNOG00000024190

Paralogs (68): RAB27B (ENSG00000041353), RAB27A (ENSG00000069974), RAB7A (ENSG00000075785), RABL2B (ENSG00000079974), RAB21 (ENSG00000080371), RAB10 (ENSG00000084733), RAB18 (ENSG00000099246), RAB36 (ENSG00000100228), IFT27 (ENSG00000100360), RAB40AL (ENSG00000102128), RAB11A (ENSG00000103769), RAB2A (ENSG00000104388), RAB3D (ENSG00000105514), RAB3A (ENSG00000105649), RAB5C (ENSG00000108774), RAB34 (ENSG00000109113), RAB5B (ENSG00000111540), RAB35 (ENSG00000111737), RAB23 (ENSG00000112210), DNAJC27 (ENSG00000115137), RAB29 (ENSG00000117280), RAB32 (ENSG00000118508), RAB14 (ENSG00000119396), RAB9B (ENSG00000123570), RAB9A (ENSG00000123595), RAB38 (ENSG00000123892), RAB22A (ENSG00000124209), RAB17 (ENSG00000124839), RAB2B (ENSG00000129472), RAB25 (ENSG00000132698), RAB33A (ENSG00000134594), RAB30 (ENSG00000137502), RAB1A (ENSG00000138069), RAB20 (ENSG00000139832), RAB15 (ENSG00000139998), RAB40B (ENSG00000141542), RAB13 (ENSG00000143545), RABL2A (ENSG00000144134), RAB5A (ENSG00000144566), RAB19 (ENSG00000146955)

Protein

Protein identifiers

Ras and EF-hand domain-containing protein — Q8IZ41 (reviewed: Q8IZ41)

Alternative names: Ras-related protein Rab-45

All UniProt accessions (1): Q8IZ41

UniProt curated annotations — full annotation on UniProt →

Function. Rab GTPase that acts as a dynein adapter protein, thereby activating dynein-mediated transport and dynein-dynactin motility on microtubules. RASEF-mediated dynein motility is Ca(2+)-independent. Also regulates the formation and sorting of zymogen granules and secretion of digestive enzymes by pancreatic acinar cells.

Subunit / interactions. Homodimer. Interacts with the dynein-dynactin complex.

Subcellular location. Cytoplasm. Perinuclear region. Golgi apparatus. Early endosome. Late endosome. Lysosome.

Tissue specificity. Down-regulated in cutaneous melanoma cells but not in breast cancer cells.

Similarity. Belongs to the small GTPase superfamily. Rab family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8IZ41-1	1	yes
Q8IZ41-2	2

RefSeq proteins (1): NP_689786* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001806	Small_GTPase	Family
IPR002048	EF_hand_dom	Domain
IPR005225	Small_GTP-bd	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR018247	EF_Hand_1_Ca_BS	Binding_site
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR050227	Rab	Family

Pfam: PF00071, PF13499

Catalyzed reactions (Rhea), 1 shown:

• GTP + H2O = GDP + phosphate + H(+) (RHEA:19669)

UniProt features (77 total): binding site 36, helix 13, strand 8, region of interest 5, compositionally biased region 3, domain 2, modified residue 2, splice variant 2, mutagenesis site 2, chain 1, sequence variant 1, turn 1, coiled-coil region 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
2P5S	X-RAY DIFFRACTION	2.15
2PMY	X-RAY DIFFRACTION	2.3

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8IZ41-F1	70.91	0.29

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (36): 21; 23; 25; 27; 29; 32; 55; 57; 59; 61; 66; 551 …

Post-translational modifications (2): 377, 383

Mutagenesis-validated functional residues (2):

Position	Phenotype
555	impairs nucleotide binding and perinuclear localization.
600	favors gtp association.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 113 (showing top): PEREZ_TP63_TARGETS, GOBP_VESICLE_MEDIATED_TRANSPORT, GOBP_EXOCYTOSIS, BILD_E2F3_ONCOGENIC_SIGNATURE, GOBP_SECRETION, PYEON_CANCER_HEAD_AND_NECK_VS_CERVICAL_UP, TGANTCA_AP1_C, GOBP_CALCIUM_ION_REGULATED_EXOCYTOSIS, PEREZ_TP53_AND_TP63_TARGETS, TGGAAA_NFAT_Q4_01, GOCC_ENDOLYSOSOME, CHARAFE_BREAST_CANCER_LUMINAL_VS_MESENCHYMAL_UP, chr9q21, GOMF_GTPASE_ACTIVITY, GOMF_GDP_BINDING

GO Biological Process (2): vesicle-mediated transport (GO:0016192), zymogen granule exocytosis (GO:0070625)

GO Molecular Function (8): GTPase activity (GO:0003924), G protein activity (GO:0003925), calcium ion binding (GO:0005509), GTP binding (GO:0005525), GDP binding (GO:0019003), identical protein binding (GO:0042802), nucleotide binding (GO:0000166), metal ion binding (GO:0046872)

GO Cellular Component (6): cytoplasm (GO:0005737), early endosome (GO:0005769), Golgi apparatus (GO:0005794), cytosol (GO:0005829), endolysosome (GO:0036019), perinuclear region of cytoplasm (GO:0048471)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
cytoplasm	3
guanyl ribonucleotide binding	2
endosome	2
transport	1
cellular process	1
calcium-ion regulated exocytosis	1
ribonucleoside triphosphate phosphatase activity	1
GTPase activity	1
molecular function regulator activity	1
metal ion binding	1
purine ribonucleoside triphosphate binding	1
anion binding	1
protein binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
cation binding	1
intracellular anatomical structure	1
endomembrane system	1
intracellular membrane-bounded organelle	1
lysosome	1

Protein interactions and networks

STRING

808 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RASEF	FRMD3	A2A2Y4	622
RASEF	BICDL1	Q6ZP65	526
RASEF	RAB11FIP3	O75154	497
RASEF	CD34	P28906	496
RASEF	TMEM210	A6NLX4	493
RASEF	TLE1	Q04724	476
RASEF	TLE4	Q04727	469
RASEF	BICDL2	A1A5D9	460
RASEF	SMIM9	A6NGZ8	450
RASEF	ACP3	P15309	445
RASEF	GNAQ	P50148	444
RASEF	PSAT1	Q9Y617	437
RASEF	OR5H2	Q8NGV7	432
RASEF	NPAP1	Q9NZP6	424
RASEF	TTC9	Q92623	420

IntAct

28 interactions, top by confidence:

A	B	Type	Score
GDI1	RAB4A	psi-mi:“MI:0914”(association)	0.820
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
FAM9C	NDC80	psi-mi:“MI:0914”(association)	0.670
CFTR	RASEF	psi-mi:“MI:0403”(colocalization)	0.580
PPFIBP2	SNAP29	psi-mi:“MI:0914”(association)	0.530
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
RABL2B	RASEF	psi-mi:“MI:0914”(association)	0.350
CFTR	MYH7B	psi-mi:“MI:0914”(association)	0.350
MAPRE1	SCAMP1	psi-mi:“MI:0914”(association)	0.350
RASEF	BLTP3B	psi-mi:“MI:0914”(association)	0.350
GDI1	NADK	psi-mi:“MI:0914”(association)	0.350
RABL2B	CEP43	psi-mi:“MI:0914”(association)	0.350
SLC22A11	CNOT1	psi-mi:“MI:0914”(association)	0.350
	ATF6	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (51): RASEF (Affinity Capture-MS), RASEF (Affinity Capture-MS), RASEF (Affinity Capture-MS), RASEF (Affinity Capture-RNA), RASEF (Affinity Capture-MS), RASEF (Proximity Label-MS), RASEF (Negative Genetic), RASEF (Proximity Label-MS), RASEF (Proximity Label-MS), RASEF (Proximity Label-MS), SRC (Affinity Capture-MS), UHRF1BP1 (Affinity Capture-MS), UHRF1BP1L (Affinity Capture-MS), ITPR3 (Affinity Capture-MS), DYNC1LI2 (Affinity Capture-MS)

ESM2 similar proteins: A0A072VIM5, A0A0K0PU92, A2CIR7, F4IG73, F4JD14, G3LSH3, G8GTN7, O23052, O42132, O80560, P03372, P0CI65, P19785, P48423, P50242, P57717, P57753, Q0JJ01, Q29040, Q2HW56, Q2QXZ2, Q2RAQ5, Q337A0, Q53AD2, Q5D0W8, Q5YLM1, Q5ZLG9, Q69ZR2, Q6KAE5, Q6NLQ8, Q6PJI9, Q6WQJ1, Q7EZ44, Q7Z494, Q8C0M0, Q8CFE5, Q8IPH9, Q8IZ41, Q9CAJ9, Q9FDY4

Diamond homologs: A4FV54, A5WW21, C4YL11, F1PTE3, O24466, O42819, P07560, P0CY30, P0CY31, P10536, P11620, P16976, P17609, P17610, P20790, P20791, P22125, P22127, P22128, P24409, P28186, P28187, P28188, P31584, P33723, P34139, P34140, P35280, P35286, P36861, P40392, P40393, P41924, P51153, P51156, P55258, P61006, P61007, P61019, P61026

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

151 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	110
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3212 predictions. Top by Δscore:

Variant	Effect	Δscore
9:82997127:C:CC	acceptor_gain	1.0000
9:83000894:A:AC	donor_gain	1.0000
9:83000895:C:CC	donor_gain	1.0000
9:83000895:CAT:C	donor_gain	1.0000
9:83000917:T:TA	donor_gain	1.0000
9:83000927:T:A	donor_gain	1.0000
9:83000988:A:AC	donor_gain	1.0000
9:83000989:C:CC	donor_gain	1.0000
9:83000992:A:AC	donor_gain	1.0000
9:83001127:TGAC:T	acceptor_gain	1.0000
9:83001128:GACCT:G	acceptor_loss	1.0000
9:83001129:ACCTG:A	acceptor_loss	1.0000
9:83001131:C:CC	acceptor_gain	1.0000
9:83001132:T:A	acceptor_loss	1.0000
9:83003625:TAA:T	donor_gain	1.0000
9:83003626:AAA:A	donor_gain	1.0000
9:83004583:TATG:T	acceptor_gain	1.0000
9:83004585:TG:T	acceptor_gain	1.0000
9:83004587:C:CC	acceptor_gain	1.0000
9:83009756:CCTGG:C	acceptor_loss	1.0000
9:83009757:C:A	acceptor_loss	1.0000
9:83009757:C:CC	acceptor_gain	1.0000
9:83009758:T:A	acceptor_loss	1.0000
9:83012508:CGAG:C	acceptor_gain	1.0000
9:83015813:G:C	donor_gain	1.0000
9:83015896:TTTTC:T	acceptor_gain	1.0000
9:83015897:TTTC:T	acceptor_gain	1.0000
9:83015898:TTC:T	acceptor_gain	1.0000
9:83015899:TC:T	acceptor_gain	1.0000
9:83015899:TCCT:T	acceptor_loss	1.0000

AlphaMissense

4893 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:82998383:T:G	D596A	0.999
9:82990397:A:G	L704P	0.998
9:82997123:G:C	F603L	0.998
9:82997123:G:T	F603L	0.998
9:82997125:A:G	F603L	0.998
9:82998383:T:A	D596V	0.998
9:82998387:A:G	W595R	0.998
9:82998387:A:T	W595R	0.998
9:83000249:C:T	G548E	0.998
9:83000250:C:A	G548W	0.998
9:82990438:A:C	S690R	0.997
9:82990438:A:T	S690R	0.997
9:82990440:T:G	S690R	0.997
9:82992910:G:T	A679D	0.997
9:82997029:A:G	W635R	0.997
9:82997029:A:T	W635R	0.997
9:82997076:A:G	L619P	0.997
9:82998382:A:C	D596E	0.997
9:82998382:A:T	D596E	0.997
9:82998383:T:C	D596G	0.997
9:82998384:C:G	D596H	0.997
9:82998389:A:G	L594P	0.997
9:83000231:T:A	K554M	0.997
9:83000232:T:G	K554Q	0.997
9:83000234:C:T	G553E	0.997
9:83000235:C:A	G553W	0.997
9:83009731:A:G	L290P	0.997
9:82990391:C:G	R706P	0.996
9:82990395:C:G	A705P	0.996
9:82992981:C:A	K655N	0.996

dbSNP variants (sampled 300 via entrez): RS1000014293 (9:83033872 C>T), RS1000023606 (9:83120146 A>G), RS1000023799 (9:83200340 G>A), RS1000026376 (9:83073745 A>G), RS1000039906 (9:83170028 C>G,T), RS1000045823 (9:83158496 T>C), RS1000054957 (9:83199941 C>T), RS1000058055 (9:82981055 T>C,G), RS1000061700 (9:83216872 T>C), RS1000074287 (9:83066775 TAGAA>T), RS1000075272 (9:83078239 T>C), RS1000095239 (9:83030623 T>C), RS1000124194 (9:83087982 A>G), RS1000144925 (9:83108681 C>A,T), RS1000158307 (9:82997363 A>C)

Disease associations

OMIM: gene MIM:611344 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST001762_493	Obesity-related traits	8.000000e-06
GCST003773_8	Loneliness (multivariate analysis)	4.000000e-07
GCST005024_43	Pursuit maintenance gain	8.000000e-07
GCST006138_5	Resting-state electroencephalogram vigilance	3.000000e-06
GCST007576_102	Chronotype	3.000000e-10
GCST007692_83	Chronic obstructive pulmonary disease	2.000000e-08
GCST008526_11	Coffee consumption	6.000000e-07
GCST010321_16	PR interval	8.000000e-10
GCST012034_7	Sleep (1/2-day periodicity)	2.000000e-08

EFO canonical traits (7, from GWAS)

EFO ID	Trait name
EFO:0005109	energy expenditure
EFO:0007865	loneliness measurement
EFO:0008433	pursuit maintenance gain measurement
EFO:0004357	electroencephalogram measurement
EFO:0008328	chronotype measurement
EFO:0006781	coffee consumption measurement
EFO:0004462	PR interval

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

50 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	6
trichostatin A	affects cotreatment, increases expression	3
Cadmium Chloride	increases expression, decreases expression	3
methylmercuric chloride	increases expression	2
sodium arsenite	decreases expression	2
entinostat	increases expression, affects cotreatment	2
Panobinostat	increases expression, affects cotreatment	2
Benzo(a)pyrene	affects methylation, decreases methylation	2
Estradiol	decreases expression, affects cotreatment	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	increases expression, decreases expression	2
terbufos	increases methylation	1
benzo(e)pyrene	affects methylation	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
aflatoxin B2	affects methylation	1
mercuric bromide	affects cotreatment, increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
belinostat	increases expression	1
abrine	increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
jinfukang	affects cotreatment, decreases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Temozolomide	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Cisplatin	affects cotreatment, decreases expression	1
Coumestrol	affects cotreatment, decreases expression	1
Demecolcine	increases expression	1
Fonofos	increases methylation	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.